News from antengene corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 12, 2020, 18:00 ET Australian Therapeutic Goods Administration Approves the First Phase I Trial of ATG-017 for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies

Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company, announced today the authorization of the...


Jul 19, 2020, 20:00 ET Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and...


Jul 01, 2020, 20:16 ET ­Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions

ntengene Corporation today announced its appointment of Zhinuan Yu, Ph.D., as Corporate Vice President (CVP) of Biometrics and Regulatory Enabling...


Jun 08, 2020, 08:00 ET Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer

Antengene Corporation (Antengene) today announced its appointment of Mr. Donald Lung as Chief Financial Officer (CFO), effective June 8, 2020. Donald ...


May 05, 2020, 08:30 ET Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets

Antengene Corporation (Antengene) today announced a broadened partnership and territory expansion agreement with Karyopharm Therapeutics Inc....


Apr 14, 2020, 08:00 ET Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Antengene announced today that it has dosed the first patient in Taiwan, China in its phase 1 open-label clinical trial of ATG-019 (KPT-9274), a dual ...


Apr 13, 2020, 08:00 ET Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions

Antengene Corporation today announced the appointment of Mr. Thomas Karalis as Head of Asia Pacific Regions. In this position, Tom will be...


Jan 08, 2020, 07:00 ET Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors

The Antengene board today announced the appointment of Mr. Mark J. Alles as an independent director of the company, effective January 2, 2020. Mr....


Jan 06, 2020, 07:00 ET Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer

Antengene Corporation today announced its appointment of Mr. John Chin, MBA, as Chief Business Officer (CBO). He will be responsible for the...


Nov 06, 2019, 11:31 ET Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

Antengene Corporation today announced that it has entered into a licensing agreement with AstraZeneca (LSE/STO/NYSE: AZN) under which Antengene has...


Jan 01, 2019, 19:15 ET Antengene Corporation Raises $120 Million in Series B Financing

Antengene Corporation (Antengene), a clinical stage therapeutics company focused on oncology, announced today that it has completed a $120 million...